Autonomix Medical Inc. (AMIX)
NASDAQ (CM) NASDAQ (CM) Primary 
Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why
Autonomix Medical, Inc. (AMIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Autonomix Medical, Inc. AMIX recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management.
AMIS Stock Surges After RF Ablation Trial Unveils Positive Results
Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.
Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.
Why Is Nao-Cap Neurology Focused Autonomix Medical Stock Trading Higher On Monday?
Autonomix Medical, Inc. AMIX stock is trading higher on Monday, with a strong session volume of 6.11 million compared to the average volume of 22.87 thousand, as per data from Benzinga Pro.
Why Is Autonomix Medical (AMIX) Stock Down 17% Today?
Autonomix Medical (NASDAQ: AMIX ) stock is taking a beating on Tuesday after the development stage medical device company saw its shares undergo a rally yesterday. That came as it provided updates on its pancreatic cancer pain management device.
Why Is Autonomix Medical (AMIX) Stock Up 120% Today?
Medical device firm Autonomix Medical (NASDAQ: AMIX ) popped into traders' radar on Monday, peaking at 150% before engaging in choppy trading. An announcement of a licensing agreement with RF Innovations, a privately held medical technology specialist, catapulted sentiment.
